Approximately 70% of breast cancers are hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–). This histologic subtype represents a clinical challenge: treatment options are limited, and women with advanced HR+/HER2– disease who have progressed on other therapies are over-represented among those who die of breast cancer. A novel class of therapies, cyclin-dependent kinase (CDK) 4/6 inhibitors—with three recently approved agents—now expands the therapeutic options for metastatic HR+/HER2- disease. This interactive, case-based activity examines evidence supporting use of these new therapies as an adjunct to endocrine therapy, factors for patient selection, and strategies for managing adverse events and improving patient adherence to therapy.
Case study with interactive benchmarking
To improve awareness of the appropriate use of novel treatments for HR+/HER2– metastatic breast cancer, aid the management of side effects, and provide strategies for improving patient adherence to therapy.
After completing this activity, participants should be better able to:
- Evaluate evidence for the use of CDK4/6 inhibitors in the management of HR+ metastatic breast cancer, including their appropriate timing and use in conjunction with endocrine therapy
- Identify therapeutic options for patients with advanced HR+/HER2– breast cancer, based on available evidence and individual patient factors
- Formulate strategies for optimizing outcomes in patients with metastatic breast cancer, including strategies for improving team-based care, promoting patient adherence to therapy, and effectively managing side effects
Oncology nurse practitioners, physician assistants, and nurses
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing contact hours: 0.50, which includes 0.50 hours of pharmacology credit
CNE course advisor: Katie Zahasky, RN, MA, CNP, Rochester, Minnesota
This program has been reviewed and is approved for a maximum of 0.50 AAPA Category 1 CME credits by the AAPA Review Panel. Approval is valid for one year from the issue date of November 30, 2017. Participants may submit the post-test at any time during that period.
This program was planned in accordance with AAPA CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, the AAPA, or Novartis.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are expected to disclose to the audience any significant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Tolaney: research support: Exelixis, Genentech, Lilly, Novartis, Pfizer.
The Planning Committee for this activity included Ruth Cohen and Devera Pine of Continuing Education Alliance; Katie Zahasky, RN, MA, CNP, of Winona, Minnesota; and Jessica Garner, MMS, PA-C, of the University of the Pacific. The members of the Planning Committee have no significant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Read the eCase in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 66%.
The estimated time to complete this activity is 0.50 hours.
Release date: November 30, 2017
Expiration date: November 30, 2018
© 2018 Practicing Clinicians Exchange. All Rights Reserved. NPCE92917